ArticleJournal of bone and mineral metabolism2007
Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation.
Article in Journal of bone and mineral metabolism, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 86 citations in OpenAlex.
- Causal relationship between Interleukin-27 expression levels and osteoporosis: a bidirectional mendelian randomization study.BMC musculoskeletal disorders · 2024Article
- How does Hashimoto's thyroiditis affect bone metabolism?Reviews in endocrine & metabolic disorders · 2023Review
- Mechanism of regulating macrophages/osteoclasts in attenuating wear particle-induced aseptic osteolysis.Frontiers in immunology · 2023Review
- Review
- Systemic IL-27 administration prevents abscess formation and osteolysis via local neutrophil recruitment and activation.Bone research · 2022Article
- Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator.International journal of molecular sciences · 2022Review
- No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors.Frontiers in immunology · 2022Review
- IL-27 Modulates the Cytokine Secretion in the T Cell-Osteoclast Crosstalk During HIV Infection.Frontiers in immunology · 2022Article
- IL-23 orchestrating immune cell activation in arthritis.Rheumatology (Oxford, England) · 2021Article
- IL-23 receptor deficiency results in lower bone mass via indirect regulation of bone formation.Scientific reports · 2021Article
- Osteoblast role in the pathogenesis of rheumatoid arthritis.Molecular biology reports · 2021Review
- JAK/STAT pathway and molecular mechanism in bone remodeling.Molecular biology reports · 2020Review
- Applying precision medicine to unmet clinical needs in psoriatic disease.Nature reviews. Rheumatology · 2020Review
- New insights into IL-17/IL-23 signaling in ankylosing spondylitis (Review).Experimental and therapeutic medicine · 2020Review
- Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.Nature reviews. Rheumatology · 2018Review
- The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.European journal of immunology · 2018Review
- Interferon-Gamma-Mediated Osteoimmunology.Frontiers in immunology · 2018Review
- Interleukin-35 Inhibits TNF-α-Induced Osteoclastogenesis and Promotes ApoptosisFrontiers in immunology · 2018Article
- Combination analysis of NOS3, ABCB1 and IL23R polymorphisms with alcohol-induced osteonecrosis of the femoral head risk in Chinese males.Oncotarget · 2017Article
- Interleukin 27 (IL-27) Alleviates Bone Loss in Estrogen-deficient Conditions by Induction of Early Growth Response-2 Gene.The Journal of biological chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-23 and IL-27 are IL-6/IL-12 family members that play a role in the regulation of T helper 1 cell differentiation. Cytokines are known to be involved in the bone remodeling process, although the effects of IL-23 and IL-27 have not been clarified. In this study, we examined the possible roles of these cytokines on osteoblast phenotypes and osteoclastogenesis. We found that IL-27 induced signal transducers and activators of transcription 3 activation in osteoblasts. However, neither IL-23 nor IL-27 showed any significant effects on alkaline phosphatase activity, receptor activator of nuclear factor kappaB ligand (RANKL) expression, mRNA expression such as alkaline phosphatase type I procollagen, or the proliferation of osteoblasts. Osteoclastogenesis from bone marrow cells induced by soluble RANKL was partially inhibited by IL-23 and IL-27 with reduced multinucleated cell numbers, but these interleukins did not affect the proliferation of osteoclast progenitor cells. These results indicate that IL-23 and IL-27 could partly modify cell fusion or the survival of multinucleated osteoclasts. On the other hand, partially purified T cells, which are activated by 2 microg/ml anti-CD3 antibody, completely inhibited osteoclastogenesis by M-CSF/RANKL. On using T cells activated with 0.2 microg/ml anti-CD3 antibody, in which osteoclastogenesis was partially inhibited, the interleukins had additive effects for inhibiting osteoclastogenesis. Although the consequences of phosphorylated signals in osteoblasts have not been identified, IL-23 and IL-27, partly and indirectly through activated T cells, inhibited osteoclastogenesis, indicating that these interleukins may protect against bone destructive autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.